> Detailanzeige

Morrison, Vicki A.; Frizzera, Glauco; Arthur, Diane C.; Ogle, Kathleen M.; Hurd, David D.; Bloomfield, Clara D.; Peterson, Bruce A.

Prognostic factors for therapeutic outcome of diffuse small non‐cleaved cell lymphoma in adults

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Prognostic factors for therapeutic outcome of diffuse small non‐cleaved cell lymphoma in adults
  • Beteiligte: Morrison, Vicki A.; Frizzera, Glauco; Arthur, Diane C.; Ogle, Kathleen M.; Hurd, David D.; Bloomfield, Clara D.; Peterson, Bruce A.
  • Erschienen: Wiley, 1994
  • Erschienen in: American Journal of Hematology
  • Sprache: Englisch
  • DOI: 10.1002/ajh.2830460408
  • ISSN: 0361-8609; 1096-8652
  • Schlagwörter: Hematology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title><jats:p>Most reports of prognosis and therapy in diffuse small non‐cleaved cell lymphoma (DSNCL), an aggressive high‐grade non‐Hodgkin's lymphoma (NHL) which appears to be of two histopathologic subtypes, have included predominantly a pediatric population and very few adults. We studied 20 newly diagnosed, previously untreated adults with DSNCL. Three patients had Ann Arbor Stage I disease, five Stage II, and 12 Stage IV. Bone marrow involvement was present in seven of 20 (35%) patients; no patient had central nervous system involvement at diagnosis. Clonal chromosomal abnormalities were found on cytogenetic analysis of all 12 cases studied. Ten patients had specific recurring translocations, including t(8;14) (q23;q32) (five patients), t(14;18) (q32;q21) (four patients), and t(2;8) (p12;q24) (one patient). Induction chemotherapy with the COMP regimen (cyclophosphamide, vincristine, methotrexate, and prednisone) or a variant schedule of the same drugs resulted in complete remission for 13 patients (65%), and partial remission for 5 patients (25%). Clinical characteristics predictive of a favorable response to induction therapy included Stage I or II disease, a normal lactic dehydrogenase (LDH), and performance status (PS) of 0 or 1. Remission duration ranged from two to 125+ (median 37+) months. Survival ranged from one to 126+ (median 23) months; ten patients (50%) remain alive, nine with no active disease. Factors predictive of longer survival included achievement of a complete remission with induction therapy, a normal LDH, and PS 0 or 1. As in children with DSNCL, long‐term disease‐free survival may be achieved in adults with combination chemotherapy. © 1994 Wiley‐Liss, Inc.</jats:p>